Lectin recognition and hepatocyte endocytosis of GalNAc-decorated nanostructured lipid carriers
Liver is the main organ for metabolism but is also subject to various pathologies, from viral, genetic, cancer or metabolic origin. There is thus a crucial need to develop efficient liver-targeted drug delivery strategies. Asialoglycoprotein receptor (ASGPR) is a C-type lectin expressed in the hepatocyte plasma membrane that efficiently endocytoses glycoproteins exposing galactose (Gal) or N-acetylgalactosamine (GalNAc). Its targeting has been successfully used to drive the uptake of small molecules decorated with three or four GalNAc, thanks to an optimisation of their spatial arrangement. Herein, we assessed the biological properties of highly stable nanostructured lipid carriers (NLC) made of FDA-approved ingredients and formulated with increasing amounts of GalNAc. Cellular studies showed that a high density of GalNAc was required to favour hepatocyte internalisation via the ASGPR pathway. Interaction studies using surface plasmon resonance and the macrophage galactose-lectin as GalNAc-recognising lectin confirmed the need of high GalNAc density for specific recognition of these NLC. This work is the first step for the development of efficient nanocarriers for prolonged liver delivery of active compounds.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Journal of drug targeting - 29(2021), 1 vom: 01. Jan., Seite 99-107 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gauthier, Laura [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.12.2021 Date Revised 14.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/1061186X.2020.1806286 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315078987 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315078987 | ||
| 003 | DE-627 | ||
| 005 | 20231225154131.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/1061186X.2020.1806286 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1050.xml |
| 035 | |a (DE-627)NLM315078987 | ||
| 035 | |a (NLM)32936032 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gauthier, Laura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lectin recognition and hepatocyte endocytosis of GalNAc-decorated nanostructured lipid carriers |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Liver is the main organ for metabolism but is also subject to various pathologies, from viral, genetic, cancer or metabolic origin. There is thus a crucial need to develop efficient liver-targeted drug delivery strategies. Asialoglycoprotein receptor (ASGPR) is a C-type lectin expressed in the hepatocyte plasma membrane that efficiently endocytoses glycoproteins exposing galactose (Gal) or N-acetylgalactosamine (GalNAc). Its targeting has been successfully used to drive the uptake of small molecules decorated with three or four GalNAc, thanks to an optimisation of their spatial arrangement. Herein, we assessed the biological properties of highly stable nanostructured lipid carriers (NLC) made of FDA-approved ingredients and formulated with increasing amounts of GalNAc. Cellular studies showed that a high density of GalNAc was required to favour hepatocyte internalisation via the ASGPR pathway. Interaction studies using surface plasmon resonance and the macrophage galactose-lectin as GalNAc-recognising lectin confirmed the need of high GalNAc density for specific recognition of these NLC. This work is the first step for the development of efficient nanocarriers for prolonged liver delivery of active compounds | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a N-acetylgalactosamine | |
| 650 | 4 | |a asialoglycoprotein receptor | |
| 650 | 4 | |a hepatocytes | |
| 650 | 4 | |a macrophage galactose-lectin | |
| 650 | 4 | |a nanostructured lipid carriers | |
| 650 | 4 | |a surface functionalisation | |
| 650 | 4 | |a targeted drug delivery | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Lectins |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 650 | 7 | |a Acetylgalactosamine |2 NLM | |
| 650 | 7 | |a KM15WK8O5T |2 NLM | |
| 700 | 1 | |a Chevallet, Mireille |e verfasserin |4 aut | |
| 700 | 1 | |a Bulteau, Francois |e verfasserin |4 aut | |
| 700 | 1 | |a Thépaut, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Delangle, Pascale |e verfasserin |4 aut | |
| 700 | 1 | |a Fieschi, Franck |e verfasserin |4 aut | |
| 700 | 1 | |a Vivès, Corinne |e verfasserin |4 aut | |
| 700 | 1 | |a Texier, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Deniaud, Aurélien |e verfasserin |4 aut | |
| 700 | 1 | |a Gateau, Christelle |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of drug targeting |d 1996 |g 29(2021), 1 vom: 01. Jan., Seite 99-107 |w (DE-627)NLM074733958 |x 1029-2330 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2021 |g number:1 |g day:01 |g month:01 |g pages:99-107 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/1061186X.2020.1806286 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2021 |e 1 |b 01 |c 01 |h 99-107 | ||